Current Practices for Out of Specification in Indian Pharma

Objectives: This study focuses on understanding why Out of Specification (OOS) results are commonly reported by the United State Food and Drug Administration (USFDA) in official letters given to Indian Drug companies. Methodology: The author reviewed several sources including USFDA Form 483 reports, official warning letters, and global regulatory guidelines such as those from the USFDA and World Health Organization (WHO). The study mainly analyzed letters from the years 2023 and 2024, while older data from 2019 to 2022 were reviewed for reference. Results: The analysis showed that many companies failed to properly investigate OOS results. Main reasons included lack of scientific justification, poor documentation, and failure to find the actual root cause. Some companies invalidated failing results without proper evidence and did not check other batches that could also be affected. The Quality Unit did not follow clear procedures for investigating failures. Conclusion: Data shows that training on OOS guidelines, better documentation, and strong investigation procedures are essential to avoid such issues. More research is needed to find why Indian companies struggle with OOS compliance and how it can be improved. A major limitation of the study was difficulty in reviewing all data.